|N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin.|
|PMID: 19098114 Owner: NLM Status: MEDLINE|
|Galectin-3 (Gal-3) is secreted by activated macrophages. In hypertension, Gal-3 is a marker for hypertrophic hearts prone to develop heart failure. Gal-3 infused in pericardial sac leads to cardiac inflammation, remodeling, and dysfunction. N-acetyl-seryl-aspartyl-lysyl-proline (Ac-SDKP), a naturally occurring tetrapeptide, prevents and reverses inflammation and collagen deposition in the heart in hypertension and heart failure postmyocardial infarction. In the present study, we hypothesize that Ac-SDKP prevents Gal-3-induced cardiac inflammation, remodeling, and dysfunction, and these effects are mediated by the transforming growth factor (TGF)-beta/Smad3 signaling pathway. Adult male rats were divided into four groups and received the following intrapericardial infusion for 4 wk: 1) vehicle (saline, n = 8); 2) Ac-SDKP (800 microg x kg(-1) x day(-1), n = 8); 3) Gal-3 (12 microg/day, n = 7); and 4) Ac-SDKP + Gal-3 (n = 7). Left ventricular ejection fraction, cardiac output, and transmitral velocity were measured by echocardiography; inflammatory cell infiltration, cardiomyocyte hypertrophy, and collagen deposition in the heart by histological and immunohistochemical staining; and TGF-beta expression and Smad3 phosphorylation by Western blot. We found that, in the left ventricle, Gal-3 1) enhanced macrophage and mast cell infiltration, increased cardiac interstitial and perivascular fibrosis, and causes cardiac hypertrophy; 2) increased TGF-beta expression and Smad3 phosphorylation; and 3) decreased negative change in pressure over time response to isoproterenol challenge, ratio of early left ventricular filling phase to atrial contraction phase, and left ventricular ejection fraction. Ac-SDKP partially or completely prevented these effects. We conclude that Ac-SDKP prevents Gal-3-induced cardiac inflammation, fibrosis, hypertrophy, and dysfunction, possibly via inhibition of the TGF-beta/Smad3 signaling pathway.|
|Yun-He Liu; Martin D'Ambrosio; Tang-dong Liao; Hongmei Peng; Nour-Eddine Rhaleb; Umesh Sharma; Sabine André; Hans-J Gabius; Oscar A Carretero|
Related Documents :
|17454834 - Synergistically therapeutic effects of vegf165 and angiopoietin-1 on ischemic rat myoca...
9011634 - Regression of hypertrophy after myocardial infarction is produced by the chronic blocka...
19808594 - Diffusion spectrum mri tractography reveals the presence of a complex network of residu...
11682444 - Effect of long-term treatment with trandolapril on hsp72 and hsp73 induction of the fai...
22812924 - Association between the amount of right-to-left shunt and infarct patterns in patients ...
10942494 - Successful application of extracorporeal membrane oxygenation and intra-aortic balloon ...
|Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't Date: 2008-12-19|
|Title: American journal of physiology. Heart and circulatory physiology Volume: 296 ISSN: 0363-6135 ISO Abbreviation: Am. J. Physiol. Heart Circ. Physiol. Publication Date: 2009 Feb|
|Created Date: 2009-01-27 Completed Date: 2009-03-12 Revised Date: 2012-10-09|
Medline Journal Info:
|Nlm Unique ID: 100901228 Medline TA: Am J Physiol Heart Circ Physiol Country: United States|
|Languages: eng Pagination: H404-12 Citation Subset: IM|
|Hypertension and Vascular Research Division, Department of Internal Medicine, Henry Ford Hospital, Detroit, MI, USA.|
|APA/MLA Format Download EndNote Download BibTex|
Anti-Inflammatory Agents / administration & dosage, blood, pharmacology*
Blood Pressure / drug effects
Body Weight / drug effects
Cardiac Output / drug effects
Cardiomegaly / chemically induced, metabolism, physiopathology, prevention & control*
Cardiotonic Agents / administration & dosage, blood, pharmacology*
Collagen / metabolism
Disease Models, Animal
Heart Rate / drug effects
Hemodynamics / drug effects*
Inflammation / chemically induced, metabolism, physiopathology, prevention & control*
Isoproterenol / pharmacology
Macrophages / drug effects, pathology
Mast Cells / drug effects, pathology
Myocardial Contraction / drug effects
Myocardium / metabolism, pathology
Oligopeptides / administration & dosage, blood, pharmacology*
Signal Transduction / drug effects
Smad3 Protein / metabolism
Stroke Volume / drug effects
Transforming Growth Factor beta / metabolism
Ventricular Function, Left / drug effects*
Ventricular Remodeling / drug effects*
|HL071806/HL/NHLBI NIH HHS; HL28982/HL/NHLBI NIH HHS; R01 HL071806/HL/NHLBI NIH HHS|
|0/Anti-Inflammatory Agents; 0/Cardiotonic Agents; 0/Galectin 3; 0/Madh3 protein, rat; 0/Oligopeptides; 0/Smad3 Protein; 0/Transforming Growth Factor beta; 120081-14-3/goralatide; 7683-59-2/Isoproterenol; 9007-34-5/Collagen|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Right ventricular free wall circumferential strain reflects graded elevation in acute right ventricu...
Next Document: Roles of Cx43-associated protein kinases in suppression of gap junction-mediated chemical coupling b...